Apimeds, Inc. US Chief Operating Officer Robert Brooks PhD announced the company received a clearance letter from the US Food & Drug Administration on December 22nd authorizing the company to proceed with its Phase III clinical trial. Apimeds plans the launch of its Phase III Apitox, a honeybee toxin, for the indication of pain and inflammation of osteoarthritis
Clinical Trials to Start for Bee Venom Arthritis Product
Apimeds, Inc. US Chief Operating Officer Robert Brooks PhD announced the company received a clearance letter from the US Food & Drug Administration on December 22nd authorizing the company to proceed with its Phase III clinical trial. Apimeds plans the launch of its Phase III Apitox, a honeybee toxin, for the indication of pain and inflammation of osteoarthritis
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment